

DR. THOMAS N. THOMPSON

MANUSCRIPTS/REVIEWS/CHAPTERS.

Drug Metabolism In-vitro and In-vivo Results: How do These Data Support Drug Discovery? **Thomas N. Thompson**, in "Using Mass Spectrometry for Drug Metabolism" (Walter Korfmacher, ed.) CRC Press, Boca Raton, FL, 2005

A Graphical Method for Estimating Oral Bioavailability of Drugs in Humans and Other Species from Their Caco-2 Permeability and *In vitro* Liver Enzyme Metabolic Stability Rates. Arun K. Mandagere, **Thomas N. Thompson**, and Kin-Kai Hwang. *J Med Chem* 45(2) 304-311 2002

Optimization of Metabolic Stability as a Goal of Modern Drug Design **Thomas N. Thompson** *Medicinal Research Reviews*, 21(5) 412-449 (2001)

Evaluation of the BBMEC model for screening the CNS permeability of drugs Kenneth W. Otis, Michael L. Avery, Suzanne M. Broward-Partin, Dannette K. Hansen, Herbert W., Jr. Behlow, Dennis O. Scott, **Thomas N. Thompson** *Journal of Pharmacological and Toxicological Methods*:45(1):71-77 2001

Early ADME in support of drug discovery: The role of metabolic stability studies **Thomas N. Thompson** *Current Drug Metabolism* 1: 215-241 2000

A strategy for use of in vitro metabolism studies to evaluate potential drug-drug interactions : M100907 as a case study in "Predicting Drug Metabolism" **Thomas N. Thompson** (Natalie S. Rudolph, Ph.D. and Martha H. Tulloch, eds) *AdvanceTech Monitor*, Woburn, MA, pp 96-106, 2000

Experimental models for evaluating enzyme induction potential of new drug candidates in animals and humans, and a strategy for their use **Thompson, Thomas N.**, in "Advances in Pharmacology, Volume 43: Drug-Drug Interactions- Scientific and Regulatory Perspectives" (A.P. Li, editor) Academic Press, pp 205-229, New York, 1997

Mass balance of ¹⁴C-bismuth sucrose octasulfate in Sprague-Dawley rats: evidence for dissociation of bismuth from sucrose octasulfate. Rao, Niranjan, Brown, Paul W, Chang, Jim, **Thompson, Thomas N.**, Geary, Julie, and Otis, Kenneth W. *Biopharmaceutics and Drug Disposition*. 18(9): 743-751, 1997

Synthesis and structure-activity relationships for a series of substituted pyrrolidine NK1/NK2 receptor antagonists. Burkholder TP. Kudlacz EM. Maynard GD. Liu XG. Le TB. Webster ME. Horgan SW. Wenstrup DL. Freund DW. Boyer F. Bratton L. Gross RS. Knippenberg RW. Logan DE. Jones BK. Chen TM. Geary JL. Correll MA. Poole JC. Mandagere AK. **Thompson TN.** Hwang KK. *Bioorganic & Medicinal Chemistry Letters*. 7(19):2531-2536 (1997)

Pharmacological evaluation of selected, orally active peptidyl inhibitors of human neutrophil elastase. Janusz, M.J., Durham, S.L., Hare, C.M., Geary, J.L., Mandagere, A.K., Poole, J.C., **Thompson, T.N.**, Xu, D., Angelastro, M.R., Burkhart, J.P., Chen, T.M., Marquart, A.L., Peet, N.P. and Hwang, K.K. *J Pharmacol Exp Therap*, 275:1233-1238 (1995)

Effect of microsomal enzyme inducers on the pharmacokinetics of ouabain after portal and systemic administration to rats. **Thompson, T.N.** and Klaassen, C.D. *J. Pharm. Pharmacol.*, 47, 1041-1047 (1995).

Determination of ML-1035 enantiomers in plasma by chiral high performance liquid chromatography. Mandagere, A.K., Osborne, D.R., Vaughn, V., Kuo, B.-S., **Thompson, T.N.**, Chang, J.C., Battor, J.L., Geary, J.L., and Hwang, K.K. *J. Pharmaceut. Biomed. Anal.* 9, 797-803 (1991).

CGS 20625, a novel pyrazolopyridine with selective anxiolytic activity Jarvis MF. Bennett DA. Loo PA. Braunwalder AF. **Thompson TN.** Schmutz M. Yokoyoma N. Wasley JW. Williams M.. *Progress in Clinical & Biological Research.* 361:477-82, 1990.

CGS 20625, a novel pyrazolopyridine anxiolytic. William, M., Bennett D.A., Loo, P.S., Braunwalder, A.F., Amrick, C.L., Wilson, D.E., **Thompson, T.N.**, Schumate, M., Yokoyoma, N., Wasley, J.W.F. *J. Pharmacol. Exp. Ther.* 248, 89-96 (1989).

Pentopril-Cimetidine interaction caused by reduction in hepatic blood flow. Kochak, G., Rahkit, A., **Thompson, T.N.**, and Hurley, M. *J. Clin. Pharmacol.* 28, 222-227 (1988).

Synthesis of hydrophenanthrene natural products: A novel approach: 1. stereoselective synthesis of resin acid synthons. **Thompson, T.N.**, Gonzalez-Sierra, M., and McChesney, J.D. *J. Org. Chem.* 50, 4447-4450 (1985).

Stereochemistry of the reductive alkylation of α,β -epoxyketones. McChesney, J.D. and **Thompson, T.N.** *J. Org. Chem.* 50, 3473-3481 (1985).

Hepatic presystemic elimination of diethylstilbestrol in rats: effect of pretreatment with inducers of UDP-glucuronosyltransferase. **Thompson, T.N.** and Klaassen, C.D. *J. Toxicol. Environ. Health* 16, 615-629 (1985).

Oxidative and conjugative metabolism of xenobiotics by livers of cattle, sheep, swine, and rats. Smith, G.S., Watkins, J.B., Klaassen, C.D., Rozman, K., **Thompson, T.N.**, and Harvey, M.J. *J. Animal Sci.* 58, 386-395 (1984).

Depletion of hepatic UDP-glucuronic acid affects the biliary excretion of drugs. Gregus, Z., Watkins, J.B., **Thompson, T.N.**, and Klaassen, C.D. *J. Pharmacol. Exp. Ther.* 225, 256-262 (1983).

Disposition of metals after portal and systemic administration to rats. **Thompson, T.N.** and Klaassen, C.D. *Toxicol. Appl. Pharmacol.* 68, 442-450 (1983)

Hepatic phase I and phase II biotransformation in quail and trout: Comparison to other species commonly used in toxicity testing. Gregus, Z., Watkins, J.B., **Thompson, T.N.**, Harvey, M., Rozman, K., and Klaassen, C.D. *Toxicol. Appl. Pharmacol.* 67, 430-441 (1983).

Resistance of some phase II biotransformation pathways to hepatotoxins. Gregus, Z., Watkins, J.B., **Thompson, T.N.**, and Klaassen, C.D. *J. Pharmacol. Exp. Ther.* 222, 471-479 (1982).

Induction studies on the functional heterogeneity of rat liver UDP-glucuronosyltransferase. Watkins, J.B., Gregus, Z., **Thompson, T.N.**, and Klaassen, C.D. *Toxicol. Appl. Pharmacol.* 64, 439-446

Effect of microsomal enzyme inducers on soluble enzymes of hepatic phase II biotransformation. **Thompson, T.N.**, Watkins, J.B., Gregus, Z., and Klaassen, C.D. *Toxic. Appl. Pharmacol.* 66, 400-408 (1982).

Presystemic elimination of manganese in rats. **Thompson, T.N.**, and Klaassen, C.D. *Toxicol. Appl. Pharmacol.* 64, 236-243 (1982).

INVITED ORAL PRESENTATIONS:

PharmaTek U Seminar Series "Considerations of Bioavailability in Drug Development"
January 22, 2009, San Diego, CA

AAPS Kansas City Discussion Group: "A Logical Approach to the Prediction of Drug-Drug Interactions (DDI) and Its Role in Drug Development" April 11, 2006, Overland Park KS

Association of Laboratory Automation LabFusion 04 Conference, June 13-16, 2004, Boston, MA, "Recent Progress in Predicting Drug Metabolism"

Cambridge Healthtech Institute's Predictive ADME conference, November 17-19, 2003, Boston, MA, "Strategies in Lead Selection and Optimization: Application of a Graphical Model and Automated in vitro ADME Screening"

8th European ISSX Meeting, April 27 to May 1, 2003, Dijon, France "Contemporary Tools for Studying Enzyme Induction: A Report from the Consensus Group"

Center for Business Intelligence's 2nd Annual Predictive Toxicology Conference, December 12-13, 2002, Philadelphia, PA "The Role of In Vitro Drug Metabolism in the Drug Approval Process."

Annual Meeting of the American Association of Pharmaceutical Scientists, November 2002, Toronto, Canada, platform session "Contemporary Tools for Studying Enzyme Induction: A Report from the Consensus Group"

Center for Business Intelligence's 2nd Annual Predictive Toxicology Conference, June 11-12, 2001, Philadelphia, PA "The BBMEC Model As An Improved, Higher Throughput Model To Screen CNS Penetration"

Strategic Research Institute's 3rd annual conference on "New Techniques to Increase Drug Candidate Survivability" May 17-18, 2001, Somerset NJ, "An Improved, Higher Throughput In Vitro Model For Screening CNS Penetration"

University of Kansas Medical Center, February 22, 2001. "Modern Drug Discovery and Development: Two decades of progress and changes to come"

SRI meeting on "New Techniques to Increase Drug Candidate Survivability" Sept 11-12, 2000, Philadelphia, PA "The BBMEC Model as a Facile Screen For CNS Permeability Of Multiple Compounds"

AAPS, Kansas City Discussion Group, "Drug Discovery and Development Advances into the 21st Century", April 11, 2000, Kansas City, MO

University of Kansas, "Role of Metabolic Stability Studies in Rational Drug Design", March 9, 2000, Lawrence, KS

Center for Business Intelligence Conference On Drug-Drug Interactions "An in vitro strategy for evaluating drug-drug interactions (DDI) potential". February 18, 2000, Philadelphia, PA.

GBR conference on Pharmacogenomics: Commercial Developments and Practical Applications entitled "A role for genomics in modern drug development"; March 10, 1998, San Francisco, CA and August 18, 1998 Philadelphia, PA

AAPS Kansas City Discussion Group: "The role of pharmacogenetics in modern drug development" November 18, 1997, Overland Park KS

IBC's World Conference on Genetic Polymorphism entitled "A decision tree for evaluating the potential significance of early in vitro evidence of genetic polymorphism" April 8, 1997, Washington, DC

IBC's World Conference on Molecular Toxicology entitled "In vitro Model using human hepatocytes to evaluate enzyme induction potential of development compounds" February 13, 1996, Lake Buena Vista, FL

POSTER PRESENTATIONS AT NATIONAL MEETINGS

IDENTIFICATION OF PXR AGONISTS (CYP3A4 INDUCERS) IN A CELL-BASED REPORTER GENE ASSAY Maciej Czerwinski, Kevin C. Lyon, Tom Thompson, Andrew Parkinson, Lyndon Warfe, Scott Allen, Mei-Fei Yueh, and Judy Raucy, Drug Metabolism Reviews, 35 Suppl 2, #234, 2003, Presented at the 12th North American ISSX meeting, October 12-16, 2003, Providence, RI

DOSE RESPONSE RELATIONSHIP FOR CYP1A AND CYP3A IN PRIMARY CULTURES OF BEAGLE DOG HEPATOCYTES Richard A. Graham, Maciej Czerwinski, Geraldine Hamilton, Tom N. Thompson, Andrew Parkinson, and Edward L. LeCluyse, Drug Metabolism Reviews, 35 Suppl 2, #247, 2003, Presented at the 12th North American ISSX meeting, October 12-16, 2003, Providence, RI

IDENTIFICATION OF AhR AGONISTS (CYP1A2 INDUCERS) IN A CELL- BASED REPORTER GENE ASSAY Kevin C. Lyon, Maciej Czerwinski, Tom Thompson, Andrew Parkinson, Lyndon Warfe , Scott Allen, Mei-Fei Yueh, and Judy Raucy, Drug Metabolism Reviews, 35 Suppl 2, #250, 2003, Presented at the 12th North American ISSX meeting, October 12-16, 2003, Providence, RI

EFFECTS OF COMMON ORGANIC SOLVENTS ON CYP2E1 ACTIVITY IN HUMAN LIVER MICROSOMES: EFFECTS OF ORDER OF ADDITION AND PRE- INCUBATION WITH NADPH. Brandy L. Paris, Amy E. Marcum, Josh R. Clarin, Claudia N. Antequera, Lois J. Haupt Julie, A. Scheinkoenig, Brian W. Ogilvie, Tom N. Thompson, and Andrew Parkinson. Drug Metabolism Reviews, 35 Suppl 2, #359, 2003, Presented at the 12th North American ISSX meeting, October 12-16, 2003, Providence, RI

THE BOVINE BRAIN MICROVESSEL ENDOTHELIAL CELL (BBMEC) MODEL AS AN IN VITRO SCREEN FOR CNS PERMEABILITY. T.N. Thompson, M.L. Avery, K.W. Otis, D.K. Hansen, M.A. Broward, S.M. Broward-Partin. H.W. Behlow, M. Kelley, D. Scott. Drug Metabolism Reviews, 22 #351 (2001) Presented at the 6th international meeting of the ISSX, October 7-11, 2001 Munich, Germany

COMPARISON OF DRUG PERMEABILITY BETWEEN MONOLAYERS OF BRAIN MICROVESSEL ENDOTHELIAL CELLS (BMEC) AND INTESTINAL EPITHELIAL CELLS (CACO-2) Kenneth W Otis, Melinda A Correll, Michael L Avery, Dannette K Hansen. Herbert W Behlow Jr, Suzanne M Broward-Partin, James Q Rose and Thomas N Thompson Abstracts of the 2001 annual meeting of the American Association of Pharmaceutical Scientists, November 2000, Indianapolis, IN

AN APPROACH FOR ACHIEVING HIGHER THROUGHPUT IN CACO-2 ABSORPTION SCREENS USING A SIMPLIFIED EXPERIMENTAL DESIGN FOR % TRANSPORT Melinda A Correll, Suzanne M Broward-Partin, Dannette K Hansen, Herbert W Behlow Jr, M Michelle

Lewis, and James Q Rose and Thomas N Thompson Abstracts of the 2000 annual meeting of the American Association of Pharmaceutical Scientists, November 2000, Indianapolis, IN

A QUANTITATIVE DETERMINATION OF PERMEABILITY IN BOVINE BRAIN MICROVESSEL ENDOTHELIAL CELLS (BBMEC) FOR VINBLASTINE, A SUBSTRATE FOR THE P-GLYCOPROTEIN EFFLUX TRANSPORTER. Michael L Avery, Kenneth W Otis, Melinda A Correll, Suzanne M Broward-Partin, James Q Rose and Thomas N Thompson Abstracts of the 2000 annual meeting of the American Association of Pharmaceutical Scientists, November 2000, Indianapolis, IN

VALIDATION OF AN IMPROVED AUTOMATED INCUBATION PROCEDURE USED TO SCREEN METABOLIC STABILITY OF MULTIPLE COMPOUNDS IN PARALLEL Andrea Nordyke*, John K. Bestor, Phyllis P Yerino, Dannette K Hansen, Herbert W. Behlow, Terry D. Miller, Thomas N. Thompson. Abstracts of the 10th North American ISSX meeting, October 23-28 2000, Indianapolis, IN

AUTOMATED HIGH THROUGHPUT METHOD TO MEASURE ENZYME ACTIVITY OF 8 MAJOR HUMAN CYP ISOZYMES WITH LC/MS Sandra D. Love*, Xiaoying Zhang*, Paul C. Toren, Phyllis P. Yerino, Thomas N. Thompson. Abstracts of the 10th North American ISSX meeting, October 23-28 2000, Indianapolis, IN

IN-VIVO/IN VITRO CORRELATION OF THE EFFECT OF CYTOCHROME P-450 3A4 AND 2D6 INHIBITION ON M100907 PHARMACOKINETICS (PK). Doris K Robbins, Thomas N Thompson, James Shipley and Vijay O. Bhargava. 29th annual American College of Clinical Pharmacology Chicago, IL

AN IMPROVED, VALIDATED PROCESS FOR SCREENING METABOLIC STABILITY OF MULTIPLE ANALOGS IN PARALLEL. Thomas N. Thompson, Andrea Nordyke, Phyllis P Yerino, Dannette K Hansen, Herbert Behlow, Lisa A. Connor, Julie L. Geary, Arun K Mandagare and J.Chuck Poole. ACS Medicinal Chemistry symposium, Kansas City , MO, June 16, 2000

MODIFIED CACO-2 PROCEDURE ACHIEVES HIGHER THROUGHPUT IN SCREENING MULTIPLE ANALOGS FOR INTESTINAL PERMEABILITY. Melinda A. Correll, Suzanne Broward-Partin, Phyllis P Yerino, Dannette K Hansen, Herbert Behlow, Paul C Toren, and Thomas N. Thompson ACS Medicinal Chemistry symposium, Kansas City , MO, June 16, 2000

AN IMPROVED, HIGHER THROUGHPUT MODEL FOR SCREENING MULTIPLE ANALOGS FOR CNS PENETRATION. Kenneth W Otis, Dannette K Hansen, Herbert W Behlow Jr, Sue A Broward-Partin, Michael L Avery, Thomas N Thompson and Dennis Scott. ACS Medicinal Chemistry symposium, Kansas City , MO, June 16, 2000

AN IN VITRO STRATEGY FOR EVALUATING DRUG-DRUG INTERACTIONS (DDI): M100907 AS A CASE STUDY. TN Thompson, SD Burmaster, LA Connor D Larsen, KA Smith PP Yerino, U Schneider, JL Geary, JC Gorski, G Gross , AP Li. Abstracts of the 1999 annual meeting of the American Association of Pharmaceutical Scientists, November 1999, New Orleans, LA

VALIDATION OF AUTOMATED IN VITRO DRUG INHIBITION STUDIES USING THE HAMILTON MICROLAB 2200 MPH WORK STATION: INHIBITION OF TERFENADINE OXIDATION BY TROLEANDOMYCIN AND FLUCONAZOLE AS A CASE STUDY. A.K. Mandagere, P.P.Yerino, T. Miller, L.A. Connor, T. Danison J.L. Geary, T.N.Thompson. Abstracts of the 1999 annual meeting of the American Association of Pharmaceutical Scientists, November 1999, New Orleans, LA

A HIGHER THROUGHPUT METABOLIC STABILITY SCREEN. John Ho, Paul W. Brown, W. Bart Emary, Thomas N. Thompson, Paul Toren, Phyllis P. Yerino. Abstracts of the 1999 annual meeting of the American Association of Pharmaceutical Scientists, November 1999, New Orleans, LA

AN APPROACH FOR ACHIEVING HIGHER THROUGHPUT IN CACO-2 ABSORPTION SCREENS USING A 24-WELL TRANSWELL™ EXPERIMENTAL DESIGN. Melinda A. Correll, Suzanne Broward-Partin, Gail H. Hurst and Thomas N. Thompson. Abstracts of the 1999 annual meeting of the American Association of Pharmaceutical Scientists, November 1999, New Orleans, LA

IN VITRO CHARACTERIZATION OF THE CYTOCHROME P450 ISOENZYMES INVOLVED IN THE METABOLISM OF M100907, A NOVEL ANTI-PSYCHOTIC AGENT. Thomas N Thompson, Steven D. Burmaster, Gary T. Emmons, Julie L. Geary, Gerhard Gross, R. Weihl, and Danny D. Shen. Abstracts of the 9th North American ISSX meeting, October 24-28, 1999, Nashville, TN

DISPOSITION AND METABOLISM OF [14C]M100907, A NOVEL ANTIPSYCHOTIC, IN HEALTHY MALE VOLUNTEERS. Thomas N. Thompson, Paul W. Brown, Steven D. Burmaster, Gary T. Emmons, Danny R. Howard and A. Gerald Groschang. Abstracts of the 9th North American ISSX meeting, October 24-28, 1999, Nashville, TN

A DECISION TREE FOR EVALUATING THE ENZYME INDUCTION POTENTIAL OF DRUG CANDIDATES DURING THE COURSE OF PHARMACEUTICAL DEVELOPMENT Thompson, T.N., Geary, J.L., Meyer, L.A., Ling, K-H.J., Reith, M.K., Cheng, L.K. and Li, A. Abstracts of the 7th North American ISSX meeting, #194, October 1996, San Diego, CA

QUANTITATIVE WHOLE-BODY AUTORADIOGRAPHIC DETERMINATION OF 14C-ML 1035 TISSUE DISTRIBUTION IN RATS FOLLOWING INTRAVENOUS OR ORAL DOSE. Kin-Kai Hwang and Tom Thompson. Abstracts of the 1995 annual meeting of the American Association of Pharmaceutical Scientists, November 1995, West Palm Beach FL

EVALUATION OF THE HEPATIC ENZYME INDUCTION POTENTIAL OF MDL 27,192 IN SPRAGUE-DAWLEY RATS AFTER ORAL ADMINISTRATION. Julie L. Geary, Lisa A. Meyer, James C. Poole, Kenneth W. Otis, Thomas N. Thompson, Arun K. Mandagere, and Kin-Kai Hwang. Abstracts of the 4th International ISSX meeting, #166, August, 1995, Seattle, WA

SELECTION OF AN ELASTASE INHIBITOR WITH IMPROVED BIOAVAILABILITY FROM A SERIES OF STRUCTURALLY RELATED ANALOGS Thomas N. Thompson, Melinda A. Correll, Julie L. Geary, Arun K. Mandagere, Joseph P. Mooney, J. Chuck Poole, Dong Xu, Phyllis P. Yerino, and Kin-Kai Hwang. Abstracts of the 4th International ISSX meeting, #315, August, 1995, Seattle, WA

COMPARISON OF MDL 201,228 (AMINO GUANIDINE) METABOLISM IN VITRO BY LIVER 10,000 X G SUPERNATANT FROM RATS, DOGS, MONKEYS AND HUMANS. Thompson, T.N., Geary, J.L., Brown, P.W., and Hwang, K.K. *Pharmaceut. Res.* 10(10), (1993).

FORMATION OF ACIDIC METABOLITES OF TA-3090 BY RAT, DOG, AND HUMAN LIVER POSTMITOCHONDRIAL SUPERNATANT (10S). Thompson, T.N., Geary, J.L., and Hwang, K.K. *Toxicologist* 12, #140 1992.

PHARMACOKINETICS AND TISSUE DISTRIBUTION OF 14C MDL 201,012A IN RATS. Hwang, K.K., Chang, J.C., Thompson, T.N., and Drees, D.T. *Pharmaceut. Res.* 8(10), PPDM #8171, p S-268 (1991).

STEREOCHEMISTRY OF THE METABOLISM OF ML-1035 AND ITS SULFIDE METABOLITE. Thompson, T.N., Geary, J.L., and Hwang, K.K. *Pharmaceut. Res.* 8(10), PPDM #8306, p S-234 (1991).

DETERMINATION OF ML-1035 ENANTIOMERS IN PLASMA BY CHIRAL HIGH PERFORMANCE LIQUID CHROMATOGRAPHY. Mandagere, A.K., Osborne, D.R., Vaughn, V., Kuo, B.-S., Thompson, T.N., Chang, J.C., Battor, J.L., Geary, J.L., and Hwang, K.K. The 3rd International Symposium on Pharmaceutical and Biomedical Analysis, Boston, MA, April 1991.

EVALUATION OF ML1012 AS AN HEPATIC ENZYME INDUCER IN RATS, DOGS, AND MONKEYS. Thompson, T.N., Geary, J.L., Unwin, S.E., Dunn, J.J., Brown, P.W., Osborne, D.R., and Hwang, K.K. Abstracts of the Third North American ISSX meeting, October, 1990, San Diego, CA, #185.

PHARMACOKINETICS AND TISSUE DISTRIBUTION OF 14C-AMINOSALICYLIC ACID (14C-ASA) IN RATS. Hwang, K., Thompson, T., Chang, J., Mandagere, A., Drees, D., and Lacz, J., *Toxicologist* 10, #961 (1990).

ASSESSMENT OF HEPATIC ENZYME INDUCTION BY ML-1012 AS PART OF ITS SAFETY EVALUATION IN RATS. Thompson, T.N., Geary, J.L., Unwin, S.E., Lacz, J.P., and Hwang, K.K., *Toxicologist* 10, #193 (1990).

TISSUE DISTRIBUTION OF [L4C]CGS 16617 IN RATS BY WHOLE-BODY AUTORADIOGRAPHY AND QUANTITATIVE TISSUE ANALYSIS. Barna-Andrusko, B., O'Buck, A., Rufino, F., Brindle, S.D., Thompson, T.N., and Robertson, P. Abstracts of the Eastern Regional Meeting of the American Association of Pharmaceutical Sciences, September, 1987, Atlantic City, NJ.

RISING DOSE TOLERANCE STUDY (RDT): A NOVEL SCENARIO FOR OBTAINING PRECLINICAL TOXICOLOGY/DRUG METABOLISM DATA. Hazelette, J., Thompson, T.N., Mertz, B., Green, J.D., Vuolo, L., Tripp, S.L., and Robertson, P., *Toxicologist* 7, #846 (1987).

STEREOSELECTIVE SYNTHESIS OF RESIN ACID SYNTHONS. McChesney, J.D., Thompson, T.N., and Sierra, M.G. Abstracts of the 185th A.C.S. National Meeting, March 20-25, 1983, Seattle, WA, ORGN. #22.

EFFECT OF MICROSOMAL ENZYME INDUCERS ON HEPATIC PRESYSTEMIC ELIMINATION OF DIETHYLSTILBESTROL AND OUABAIN. Thompson, T.N. and Klaassen, C.D., *Pharmacologist* 25, #680 (1983).

HEPATIC PHASE I AND PHASE II BIOTRANSFORMATIONS IN QUAIL AND TROUT: COMPARISONS TO SPECIES COMMONLY USED IN TOXICITY TESTING. Watkins, J.B., Gregus, Z., Thompson, T.N., Harvey, M.J., Rozman, K., and Klaassen, C.D., *Toxicologist* 3, #646 (1983).

DIETHYL ETHER ANESTHESIA DEPLETES UDP-GLUCURONIC ACID (UDPGA) AND DEPRESSES BILIARY EXCRETION. Watkins, J.B., Gregus, Z., Thompson, T.N., and Klaassen, C.D. *Toxicologist* 3, #357 (1983).

DEPLETION OF HEPATIC UDP-GLUCURONIC ACID (UDPGA) DECREASES THE BILIARY EXCRETION OF DRUGS. Watkins, J.B., Gregus, Z., Thompson, T.N., and Klaassen, C.D., *Hepatology* 2, #119 (1982).

RESISTANCE OF SOME BIOTRANSFORMATION PATHWAYS TO HEPATOTOXINS. Watkins, J.B., Gregus, Z., Thompson, T.N., and Klaassen, C.D., *Fed. Proc.* 41, 1638 (1982).

INDUCTION OF HEPATIC PHASE II METABOLISM IN THE RAT. Thompson, T.N., Watkins, J., Gregus, Z., and Klaassen, C.D., *Toxicologist* 2, #441 (1982).

PRESYSTEMIC ELIMINATION OF DIETHYLSTILBESTROL IN RATS. Thompson, T.N. and Klaassen, C.D., *Toxicologist* 2, #505 (1982).

INDUCTION STUDIES ON THE FUNCTIONAL HETEROGENEITY OF RAT UDP-GLUCURONYLTRANSFERASE. Watkins, J.B., Gregus, Z., Thompson, T.N., and Klaassen, C.D., *Hepatology* 1, #69A (1981).

PREGNENOLONE-16 α -CARBONITRILE, AN EFFECTIVE INDUCER OF HEPATIC PHASE II BIOTRANSFORMATION IN THE RAT. Thompson, T.N., Watkins, J.B., Gregus, Z., and Klaassen, C.D., *Hepatology* 1, #63C (1981).

FIRST PASS EFFECT OF MANGANOUS CHLORIDE. Thompson, T.N. and Klaassen, C.D., *Toxicologist* 1, #432 (1981).

STEREOCHEMISTRY OF THE REDUCTIVE ALKYLATION OF CARVONE EPOXIDE. Abstracts of the 11th Midwest Regional A.C.S. Thomas N. Thompson, James D. McChesney